翻訳と辞書
Words near each other
・ GT Nexus
・ GT Pro Series
・ GT Racer
・ GT Racers
・ GSIS
・ GSIS Museo ng Sining
・ GSIS-Meralco bribery case
・ GSJ
・ GSK
・ GSK 299423
・ GSK-189,254
・ GSK-3
・ GSK-789,472
・ GSK1360707F
・ GSK2606414
GSK2831781
・ GSK3A
・ GSK3B
・ GSK716155
・ GSKB Almaz-Antey
・ GSL
・ GSL Holdings Ltd.
・ GSL-class berthing pontoon
・ GSL-class Ferry
・ GSL-class power barge
・ GSL-class service barge pontoon
・ GSL/GRSE series of Interceptor Boats
・ GSLI
・ GSLIS
・ GSLP Kudumbashree


Dictionary Lists
翻訳と辞書 辞書検索 [ 開発暫定版 ]
スポンサード リンク

GSK2831781 : ウィキペディア英語版
GSK2831781
GSK2831781 is a monoclonal antibody being developed by GlaxoSmithKline (GSK) for autoimmune diseases. The antibody targets the T cell activation marker LAG-3, which is mainly expressed in inflamed tissues. In GSK's March 2015 ''Product development pipeline'' document the antibody is listed under 'Immuno-inflammation' candidates.〔http://www.gsk.com/media/621672/product-pipeline-2015.pdf〕 GSK2831781 entered a Phase I clinical trial in psoriasis early in 2015.
== History ==
GSK2831781 originated from a chimeric monoclonal antibody to LAG-3 developed in 2008 by the French biotechnology company Immutep. That company had been built around drugs targeting LAG-3 and was associated with Frédéric Triebel, an immunologist generally regarded as a leading authority on LAG-3. In discovering the Immutep antibody, Triebel worked with two researchers from the University of Nantes, where there was an INSERM unit focused on transplantation immunology called ITUN (Institut de Transplantation Urologie Nephrologie). Triebel et al. codenamed their initial murine antibody A9H12, which became IMP731 after it had been chimerized with a human IgG1 Fc region in order to have antibody-dependent cellular cytotoxicity (ADCC) as well as complement-dependent cytotoxicity (CDC) properties.
GSK licensed the rights to develop anti-LAG-3 antibodies for autoimmune disease from Immutep in December 2010 in a total deal package worth ₤64m. GSK subsequently developed GSK2831781, its own depleting anti-LAG-3 antibody based on IMP731, around 2013 or 2014. GSK's antibody was humanized and was afucosylated for higher ADCC.
Prima BioMed, the biotech company which acquired Immutep in 2014, announced a 'single digit' million dollar milestone related to GSK2831781’s commencement of the Phase I in January 2015.〔http://www.primabiomed.com.au/investor/pm/2015/1292.php〕

抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)
ウィキペディアで「GSK2831781」の詳細全文を読む



スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース

Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.